Evidence map›Paper›PMID 27466351›Full record

ArticleClinical and vaccine immunology : CVI2016

Humanized Monoclonal Antibody That Passively Protects Mice against Systemic and Intranasal Ricin Toxin Challenge.

Greta Van Slyke, Erin K Sully, Natasha Bohorova, Ognian Bohorov, Do Kim, Michael H Pauly, Kevin J Whaley, Larry Zeitlin, Nicholas J Mantis

Abstract read
In one paragraph

Article in Clinical and vaccine immunology : CVI, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Multiple metabolic pathways are predictive of ricin intoxication in a rat model.Metabolomics : Official journal of the Metabolomic Society · 2019
    Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Greta Van SlykeDivision of Infectious Disease, Wadsworth Center, New York State Department of Health, Albany, New York, USA.ORCID http://orcid.org/0000-0003-2646-3030
Erin K SullyDivision of Infectious Disease, Wadsworth Center, New York State Department of Health, Albany, New York, USA.
Natasha BohorovaMapp Biopharmaceutical, Inc., San Diego, California, USA.
Ognian BohorovMapp Biopharmaceutical, Inc., San Diego, California, USA.
Do KimMapp Biopharmaceutical, Inc., San Diego, California, USA.
Michael H PaulyMapp Biopharmaceutical, Inc., San Diego, California, USA.
Kevin J WhaleyMapp Biopharmaceutical, Inc., San Diego, California, USA.
Larry ZeitlinMapp Biopharmaceutical, Inc., San Diego, California, USA larry.zeitlin@mappbio.com nicholas.mantis@health.ny.gov.
Nicholas J MantisDivision of Infectious Disease, Wadsworth Center, New York State Department of Health, Albany, New York, USA Department of Biomedical Sciences, School of Public Health, University at Albany, Albany, New York, USA larry.zeitlin@mappbio.com nicholas.mantis@health.ny.gov.ORCID http://orcid.org/0000-0002-5083-8640

Funding

An Antibody Immunoprotectant for Category B ToxinsR01AI098774 · NIAID · MAPP BIOPHARMACEUTICAL, INC. · PI ZEITLIN, LARRY · 2012 to 2016
$6.2M
Training in Biodefense and Emerging Infectious DiseaseT32AI055429 · NIAID · WADSWORTH CENTER · PI MCDONOUGH, KATHLEEN A · 2004 to 2014
$2.2M
Development of a monoclonal immunoprotectant for ricinR43AI091078 · NIAID · MAPP BIOPHARMACEUTICAL, INC. · PI ZEITLIN, LARRY · 2010 to 2011
$600k
NIAID NIH HHS R01 AI098774NIAID NIH HHS R43 AI091078NIAID NIH HHS T32 AI055429
6 · The paper itself

Abstract

PB10 is a murine monoclonal antibody against an immunodominant epitope on ricin toxin's enzymatic subunit. Here, we characterize a fully humanized version of PB10 IgG1 (hPB10) and demonstrate that it has potent in vitro and in vivo toxin-neutralizing activities. We also report the minimum serum concentrations of hPB10 required to protect mice against 10 times the 50% lethal dose of ricin when delivered by injection and inhalation.

Indexed as

AnimalsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntitoxinsChemical Warfare AgentsDisease Models, AnimalFemaleMice, Inbred BALB CPoisoningRicinSurvival AnalysisTreatment OutcomeAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntitoxinsChemical Warfare AgentsRicin

Identifiers

PMID27466351
PMCPMC5014922

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.